retatrutide triple agonist glp-1 gip glucagon phase 2 obesity G Agonists – Retatrutide. What is all the buzz? – Dr Girouard's Targeting GLP-1, GIP & GCG
Description
Funding This work was supported by the National Natural Science Foundation of China (31870906, 81974254, 82170470, and 82270903), Hubei Provincial Natural Science Foundation (2022CFB453), Foundation of Health Commission of Hubei (WJ2021M061, WJ2019F071), the Natural Science Foundation of the Bureau of Science and Technology of Shiyan City (grant no
Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies
Incretin agonist clinical trials most frequently reveal nausea as an adverse effect
Retatrutide's triple agonist mechanism represents the next potential frontier
It prompted major manufacturers to significantly expand global production and manufacturing capacities
This is why the larger phase 3 and cardiovascular outcomes trials are essential
